Richard Greil * Lisa Pleyer
Daniel Neureiter * Viktoria Faber
Editors

2010

Epidemiology, Pathophysiology and Treatment Options

The understanding of the genetic, epigenetic, immunological and biological causes of myeloproliferative disorders has substantially improved in the last few years. Together with refined tools in pathology, the successful establishment of mouse models mimicking at least some of the myeloproliferative disorders, and murine models allowing to carefully dissect the role of mutations and gene dosage effects of, for example JAK2, this has led to ever increasing numbers of modified classification schemes.